BidaskClub lowered shares of Paratek Pharmaceuticals (NASDAQ:PRTK) from a sell rating to a strong sell rating in a research note released on Saturday morning.
PRTK has been the topic of a number of other research reports. Zacks Investment Research raised shares of Paratek Pharmaceuticals from a hold rating to a buy rating and set a $21.00 price objective on the stock in a report on Saturday, August 5th. Cantor Fitzgerald reissued an overweight rating on shares of Paratek Pharmaceuticals in a report on Tuesday, August 8th. Raymond James Financial reissued a strong-buy rating and issued a $36.00 price objective on shares of Paratek Pharmaceuticals in a report on Thursday, August 24th. ValuEngine downgraded shares of Paratek Pharmaceuticals from a hold rating to a sell rating in a report on Monday, September 18th. Finally, Guggenheim began coverage on shares of Paratek Pharmaceuticals in a report on Tuesday, October 24th. They issued a buy rating and a $44.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Paratek Pharmaceuticals presently has an average rating of Buy and a consensus price target of $40.00.
Shares of Paratek Pharmaceuticals (NASDAQ PRTK) opened at $18.55 on Friday. Paratek Pharmaceuticals has a 12 month low of $13.10 and a 12 month high of $29.00. The company has a current ratio of 10.53, a quick ratio of 10.53 and a debt-to-equity ratio of 0.49.
COPYRIGHT VIOLATION NOTICE: “BidaskClub Lowers Paratek Pharmaceuticals (PRTK) to Strong Sell” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://sportsperspectives.com/2017/12/05/bidaskclub-lowers-paratek-pharmaceuticals-prtk-to-strong-sell.html.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.